PURPOSE: To assess the efficacy and maximum dose-intensity of a new topoisomerase I (topo I)-targeting agent, @entity13627 (9-AC), in @entity1 with relapsed or @entity706 . @entity1 AND METHODS: Eligible @entity1 had measurable disease and were considered incurable. 9-AC was infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with subsequent intrapatient escalations or reductions in 10-microg/m2/h increments based on @entity137 . To assess the impact of @entity1261 ( @entity1261 ) on dose-intensity, the first 16 @entity1 received no @entity1261 and the subsequent 29 @entity1 received @entity1261 on all cycles. RESULTS: Forty-five @entity1 received a total of 142 cycles of 9-AC. The @entity1 ' median age was 55 years, 73% had stage IV disease, and histologies included indolent and aggressive @entity1893 ( @entity1893 ) in 33% and 58% of @entity1 , respectively, and @entity978 in 9%. @entity1 had received a median of two prior chemotherapy regimens, and 67% of @entity1 had chemotherapy-sensitive disease. Of 40 assessable @entity1 , 10 (25%) achieved a partial response (PR). Chemotherapy-sensitive @entity1 had a 32% response rate compared with 8% in chemotherapy-resistant @entity1 . With a median follow-up duration of 35 months, the median event-free survival (EFS) and overall survival times were 1.5 and 12.5 months, respectively, and the median duration of response was 5 months (range, 1 to 10). @entity1261 significantly reduced the incidence of @entity1398 and @entity294 , but did not permit a significant increase in dose-intensity. CONCLUSION: 9-AC had a reasonable response rate of 25% in heavily pretreated @entity1 . The low response rate in @entity1 with chemotherapy-resistant disease suggests that there is cross-resistance between 9-AC and standard chemotherapy. However, there was no association between 9-AC response and the number of prior regimens. Due to dose-limiting @entity882 , @entity1261 support did not increase dose-intensity, although individual @entity1 benefited from the use of @entity1261 .

Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of @entity13627 in relapsed and XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor'] @entity706 :: ('MESH:D008223', 'Disease') :: ['refractory lymphomas'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity13627 :: ('MESH:C080125', 'Chemical') :: ['9-aminocamptothecin'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's lymphoma"]
@entity706 :: (MESH:D008223,Disease) :: ['refractory lymphomas']
